Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16134153 | 0.95 | KIT (1.00) | KIT | |
| SCHEMBL16134159 | 0.91 | KIT (1.00) | KIT | |
| SCHEMBL16134166 | 0.90 | KIT (1.00) | KIT | |
| SCHEMBL16134401 | 0.89 | KIT (1.00) | KIT | |
| SCHEMBL16109801 | 0.89 | KIT (1.00) | KIT | |
| SCHEMBL16134171 | 0.87 | KIT (1.00) | KIT | |
| SCHEMBL16134165 | 0.87 | KIT (1.00) | KIT | |
| SCHEMBL16134150 | 0.85 | KIT (1.00) | KIT | |
| SCHEMBL16134175 | 0.84 | KIT (1.00) | KIT | |
| SCHEMBL16134450 | 0.84 | KIT (1.00) | KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994552-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994552-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170029409-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION | 2017-02-02 | — | — | US | disclosed |
| US-20170029409-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION | 2017-02-02 | — | — | US | disclosed |
| US-9499522-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499522-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2016-11-22 | — | — | US | disclosed |
| US-20140296206-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2014-10-02 | — | — | US | disclosed |
| WO-2014160521-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS KIT MODULATORS | BLUEPRINT MEDICINES CORPORATION (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140296206-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296206-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | KIT, APC, CKMT1A; CKMT1B | KIT 1/4885 |
| US-20170029409-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | KIT, APC, CKMT1A; CKMT1B | KIT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.